

Special Issue

Role of NO in Disease: Good, Bad or Ugly

Message from the Guest Editors

L-Arginine is a precursor for NO synthesis. NO is a reactive molecule with unpaired electrons, being a ubiquitous signaling molecule, able to interact with molecular oxygen and superoxide radicals. Endothelial cells are the largest source of NO production. The antiviral effects of NO have caused considerable interest during the COVID-19 pandemic. NO impedes the binding of SARS-CoV-2 to the ACE2 receptor and counteracts viral replication. Compromised production or bioavailability of NO is associated with both arterial and venous thrombi, a frequent consequence of COVID-19. Given the multitude of powerful biological effects of NO, several attempts have been made to utilize this radical as a therapeutic agent, mainly in pulmonary hypertension. Administration of NO has focused on inhalation, which may cause the relaxation of smooth muscle cells in the pulmonary vasculature. Vasodilation results in improved perfusion to ventilated areas of lung, thereby improving oxygenation and reducing intrapulmonary shunting. However, NO is potentially harmful, since its oxidation products are toxic and may contribute to tissue damage in certain disorders.

Guest Editors

Dr. Mats B. Eriksson

Department of Surgical Sciences, Anaesthesiology and Intensive Care Medicine, Uppsala University, 751 85 Uppsala, Sweden

Prof. Dr. Anders O. Larsson

Department of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden

Deadline for manuscript submissions

closed (31 May 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/102647

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).